ENDE

Aim & Objectives of HOPE2

Based on the proceedings and results of the first funding period (see HOPE-1), the following aims will be realized within this project:

  • Improving and advancing the clinical and genetic diagnostics of hereditary retinal disorders
  • Unravelling the genetic complexity of HRDs
  • Identification and validation of neuroprotective substances and development of a suitable delivery system for treatment of hereditary retinal disorders

Due to the direct accessibility of the neuroretina to clinical investigations as wells as surgical interventions and topical delivery systems and its immune-privileged status, this neural system is an excellent model for improving and refining the diagnostics of HRDs and for developing new therapeutic strategies close to human application. This is likely to be achieved in a ten years period. In committing to this goal, the project partners of HOPE propose to focus on the following topics:

The project partners of the 'HOPE' consortium focus their research on the following topics:

  • High-resolution clinical phenotyping and genotype-based clinical investigation of HRD patients; establishment of patient cohorts for prospective therapeutical studies
  • Integrated genetic diagnostics and standardized clinical service for HRD patients
  • Unravelling the genetic complexity of HRDs
  • Establishment and validation of bioactive substances with therapeutic potency for HRDs
  • Optimization and validation of CellBead technology for the application of neuroprotective treatment in preclinical studies
  • Optimization of delivery and monitoring of safety and efficacy of cell-based neuroprotection in animal models for HRDs
Subretinale Injektion von CellBeads

Subretinal injection of CellBeads